Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice (SAIL)

Almirall

Status: Completed

Conditions: Plaque Psoriasis

Treatments: Drug: Tildrakizumab

Study type: Observational

Funder types: Industry

Identifiers

NCT04203693

NIS Study M-14745-43

Details and patient eligibility

About

The observational, non-interventional study will assess the efficacy, safety, prescription and utilization patterns of Tildrakizumab in participants with moderate to severe plaque psoriasis in routine clinical practice.

Enrollment: 331 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent form.
• Age >= 18years.
• Moderate to severe chronic plaque psoriasis diagnosis.
• Participants who have participated in Tildrakizumab (Ilumetri®) clinical trials (Cohort 1) OR participants who, according to the physician's therapeutic decision, should start the treatment with Tildrakizumab (Ilumetri®) (Cohort 2).

Exclusion criteria

• Unable to comply with the requirements of the study or who in the opinion of the study physician should not participate in the study.
• Participants meeting any of the exclusion criteria specified in the summary of product characteristics (SmPC) of Ilumetri®.

Trial design

331 participants in 2 patient groups

Cohort 1: Tildrakizumab Treated Participants

Description:

Participants will be treated with tildrakizumab who have participated in prior tildrakizumab studies

Treatment:

Drug: Tildrakizumab

Cohort 2: Newly Tildrakizumab Prescribed Participants

Description:

Participants will be newly prescribed tildrakizumab (a prescription has occurred independently of the enrolment in the study)

Treatment:

Drug: Tildrakizumab